Healthrageous, a digital health management company, and pharmaceutical company Boehringer Ingelheim have launched the SMART study with United BioSource (UBC) to evaluate a digital technology enabled self-management solution to potentially improve the health status of people with type 2 diabetes. The goal of the solution is to leverage technology in a way that makes the personalized journey of self-managing diabetes easier for patients to self-manage their disease.

Through the Institutional Review Board (IRB) approved research project, adults who have been diagnosed with type 2 diabetes for at least six months will have access to Healthrageous’ digital diabetes self-management program. The web- and smartphone-delivered program will include a personalized action plan with health behavior improvement goals, a wireless glucose meter transmitting data to clinical monitors and HbA1c at-home test kits. By combining medical claims data, this collaboration will allow an evaluation of the impact a digital diabetes platform could have on medical and pharmaceutical costs, clinical care, consumer behavior modification and device and self-reported biometric health measures.

UBC will identify and help manage the recruitment of participants from nearly a dozen U.S. employers for the study.

“Through a patient-centric design, this study will allow us to collect and integrate patient-reported data, biometric data and claims data in order to generate new insights into health behaviors, outcomes and cost utilization,” said Abbe Steel, vice president, patient and physician services, UBC.